Furthermore, pre‐treatment with this EP3 inhibitor prior to PGE2 treatment failed to dedifferentiate SSc skin MFs or to potentiate the PGE2‐elicited reduction in αSMA and collagen in SSc lung MFs (Figure S4D). This evidence concerns the gene PTGER3 and systemic sclerosis.